Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

Blood (2023) 142 (Supplement 1): 4539.

https://doi.org/10.1182/blood-2023-180730

Published: 2023

Journal Articles

Diagnosis and Outcome of Patients with Idiopathic Hypereosinophilic Syndrome and Cardiac Involvement

Johannes Lübke, Anna Hohneck, Jan Leipe, Nicole Naumann, Alice Fabarius, Wolf-Karsten Hofmann, Georgia Metzgeroth, Theano Papavassilu, Andreas Reiter, Juliana Schwaab

Blood (2023) 142 (Supplement 1): 3196.

https://doi.org/10.1182/blood-2023-187249

Published: 2023

Journal Articles

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Blood (2023) 142 (Supplement 1): 446.

https://doi.org/10.1182/blood-2023-182792

Published: 2023

Journal Articles

Predicting the Clinical Course of Treatment with Midostaurin in Patients with Advanced Systemic Mastocytosis

Johannes Lübke, Nicole Naumann, Timo Brand, Hans-Peter Horny, Martina Rudelius, Karl Sotlar, Georgia Metzgeroth, Alice Fabarius, Wolf-Karsten Hofmann, Juliana Schwaab, Andreas Reiter

Blood (2023) 142 (Supplement 1): 1834.

https://doi.org/10.1182/blood-2023-182322

Published: 2023

Journal Articles

Inter-Modality Variance of Blast Quantification in Patients with Myelodysplastic Syndrome (MDS) and Its Impact on Risk Stratification and Overall Survival

Laurenz Steiner, Navkirandeep Kaur, Alexander Streuer, Johann-Christoph Jann, Alice Fabarius, Georgia Metzgeroth, Wolf-Karsten Hofmann, Daniel Nowak, Mohamad Jawhar

Blood (2022) 140 (Supplement 1): 9831–9832.

https://doi.org/10.1182/blood-2022-168850

Published: 2022

Journal Articles

Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 3054–3055.

https://doi.org/10.1182/blood-2022-159507

Published: 2022

Journal Articles

Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)

Blood (2022) 140 (Supplement 1): 947–949.

https://doi.org/10.1182/blood-2022-159412

Published: 2022

Journal Articles

Response and Resistance to Cladribine in Patients with Advanced Systemic Mastocytosis: A Registry-Based Analysis

Johannes Lübke, Nicole Naumann, Sebastian Kreil, Georgia Metzgeroth, Hans-Peter Horny, Karl Sotlar, Nicholas C.P. Cross, Alice Fabarius, Peter Valent, Wolf-Karsten Hofmann, Juliana Schwaab, Andreas Reiter

Blood (2022) 140 (Supplement 1): 3970–3971.

https://doi.org/10.1182/blood-2022-163650

Published: 2022

Journal Articles

High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels

Blood (2019) 134 (Supplement_1): 666.

https://doi.org/10.1182/blood-2019-127127

Published: 2019

Journal Articles

Accumulation of DNA Damage and Alteration of the DNA Damage Response in Chronic Myeloid Leukemia

Henning D. Popp, Vanessa Kohl, MSc, Johanna Flach, PhD, Susanne Brendel, MTA, Helga Kleiner, MTA, Wolfgang Seifarth, PhD, Christel Weiss, PhD, Susanne Saussele, MD, Wolf-Karsten Hofmann, MD PhD, Alice Fabarius, PhD

Blood (2019) 134 (Supplement_1): 5364.

https://doi.org/10.1182/blood-2019-122698

Published: 2019

Journal Articles

Anti-Leukemic Efficacy of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies

Vanessa Kohl, MSc, Susanne Brendel, MTA, Johanna Flach, PhD, Helga Kleiner, MTA, Christel Weiss, PhD, Wolfgang Seifarth, PhD, Daniel Nowak, MD, Wolf-Karsten Hofmann, MD PhD, Alice Fabarius, PhD, Henning D. Popp

Blood (2019) 134 (Supplement_1): 5056.

https://doi.org/10.1182/blood-2019-122672

Published: 2019

Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response

Blood (2019) 134 (Supplement_1): 495.

https://doi.org/10.1182/blood-2019-130043

Published: 2019

Journal Articles

Comparison of RNA-Based Versus DNA-Based Quantitative KIT D816V Mutation Analysis Reveals Significant Disparity in Patients with Advanced Systemic Mastocytosis

Mohamad Jawhar, Nicole Naumann, Johannes Lübke, Juliana Schwaab, Oliver Hofmann, Thomas Kielsgaard Kristensen, Karl Sotlar, Verena Haselmann, Sven Schneider, Georgia Metzgeroth, Henning D. Popp, Alice Fabarius, PhD, Peter Bugert, Wolf-Karsten Hofmann, MD PhD, Andreas Reiter

Blood (2019) 134 (Supplement_1): 2955.

https://doi.org/10.1182/blood-2019-128811

Published: 2019

Journal Articles

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1647.

https://doi.org/10.1182/blood-2019-129710

Published: 2019

Journal Articles

An Increased Bone Mineral Density As an Adverse Prognostic Factor in Patients with Systemic Mastocytosis

Mohamad Jawhar, Juliana Schwaab, Nicole Naumann, Georgia Metzgeroth, Alice Fabarius, PhD, Stefan O Schoenberg, Wolf-Karsten Hofmann, MD PhD, Philipp Riffel, Andreas Reiter

Blood (2019) 134 (Supplement_1): 4185.

https://doi.org/10.1182/blood-2019-129798

Published: 2019

Journal Articles

KIT D816 Mutated / CBF-Negative Acute Myeloid Leukemia (AML): A New Poor-Risk Subtype Associated with Systemic Mastocytosis (SM-AML)

Blood (2018) 132 (Supplement 1): 1535.

https://doi.org/10.1182/blood-2018-99-115895

Published: 2018

Journal Articles

A New Prognostic Score for Advanced Systemic Mastocytosis Based on Clinical and Genetic Characteristics of 210 Consecutive Patients

Mohamad Jawhar, Juliana Schwaab, Nicole Naumann, Georgia Metzgeroth, MD, Hans-Peter Horny, Karl Sotlar, Manja Meggendorfer, PhD, Torsten Haferlach, MD, Nicholas C.P. Cross, Alice Fabarius, Wolf-Karsten Hofmann, Peter Valent, Andreas Reiter, MD

Blood (2018) 132 (Supplement 1): 349.

https://doi.org/10.1182/blood-2018-99-115804

Published: 2018

Journal Articles

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Rüdiger Hehlmann, MD, Michael Lauseker, PhD, Susanne Saussele, MD, Markus Pfirrmann, Stefan W. Krause, MD, Hans-Jochem Kolb, MD, Andreas Neubauer, MD, Dieter K. Hossfeld, Christoph Nerl, MD, Alois Gratwohl, MD, Gabriela M. Baerlocher, Dominik Heim, MD, Tim Henrik Bruemmendorf, Alice Fabarius, PhD, Claudia Haferlach, MD, Brigitte Schlegelberger, MD PhD, Martin C. Müller, MD, Sabine Jeromin, PhD, Ulrike Proetel, PhD, Katharina Kohlbrenner, PhD, Astghik Voskanyan, PhD, Sébastien Rinaldetti, Wolfgang Seifarth, PhD, Birgit Spiess, Leopold Balleisen, MD, Maria E Goebeler, MD, Mathias Hänel, MD, Anthony D. Ho, MD, J Dengler, C Falge, Lothar Kanz, MD, Claus-Henning Köhne, MD, PhD, Andreas Burchert, MD, Michael Kneba, MD PhD, Frank Stegelmann, MD, C Köhne, Hans-Walter Lindemann, C Waller, Michael Pfreundschuh, MD, Karsten Spiekermann, Wolfgang E Berdel, MD, L Müller, Matthias Edinger, MD, Jiri Mayer, Prof, MD SCs, Dietrich W Beelen, MD PhD, Martin Bentz, MD, Hartmut Link, MDPhD, Bernd Hertenstein, MD, R Fuchs, Martin Wernli, MD, F Schlegel, Rudolph Schlag, M de Wit, Lorenz Trümper, MD, H Hebarth, M Hahn, Jörg Thomalla, MD, Christof Scheid, MD, Philippe Schafhausen, MD, Walter Verbeek, MD, Michael J. Eckart, MD, Winfried Gassmann, MD PhD, Antonio Pezzutto, MD, Michael Schenk, Peter Brossart, MD, Thomas Geer, MD, Stephan Bildat, E Schäfer, Andreas Hochhaus, MD, Joerg Hasford

Blood (2017) 130 (Supplement 1): 897.

https://doi.org/10.1182/blood.V130.Suppl_1.897.897

Published: 2017

Journal Articles

Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy

Blood (2017) 130 (Supplement 1): 2916.

https://doi.org/10.1182/blood.V130.Suppl_1.2916.2916

Published: 2017

Journal Articles

Increase of DNA Damage and Alteration of the DNA Damage Response in Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

Henning D. Popp, MD, Susanne Brendel, MTA, Sabrina Ruppenthal, PhD, Helga Kleiner, MTA, Sven Schneider, MD, Torsten Schulze, MD, Christel Weiss, PhD, Frederik Wenz, MD, Wolf-Karsten Hofmann, MD, Alice Fabarius

Blood (2017) 130 (Supplement 1): 4300.

https://doi.org/10.1182/blood.V130.Suppl_1.4300.4300

Published: 2017

NARROW

ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

Diagnosis and Outcome of Patients with Idiopathic Hypereosinophilic Syndrome and Cardiac Involvement

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Predicting the Clinical Course of Treatment with Midostaurin in Patients with Advanced Systemic Mastocytosis

Inter-Modality Variance of Blast Quantification in Patients with Myelodysplastic Syndrome (MDS) and Its Impact on Risk Stratification and Overall Survival

Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms

Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)

Response and Resistance to Cladribine in Patients with Advanced Systemic Mastocytosis: A Registry-Based Analysis

High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels

Accumulation of DNA Damage and Alteration of the DNA Damage Response in Chronic Myeloid Leukemia

Anti-Leukemic Efficacy of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies

Comparison of RNA-Based Versus DNA-Based Quantitative KIT D816V Mutation Analysis Reveals Significant Disparity in Patients with Advanced Systemic Mastocytosis

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

An Increased Bone Mineral Density As an Adverse Prognostic Factor in Patients with Systemic Mastocytosis

KIT D816 Mutated / CBF-Negative Acute Myeloid Leukemia (AML): A New Poor-Risk Subtype Associated with Systemic Mastocytosis (SM-AML)

A New Prognostic Score for Advanced Systemic Mastocytosis Based on Clinical and Genetic Characteristics of 210 Consecutive Patients

Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase

Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy

Increase of DNA Damage and Alteration of the DNA Damage Response in Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only